Octreotide
-
Camurus’ Oczyesa® Approved for Acromegaly Treatment in EU
The European Commission has granted marketing authorization for Oczyesa®, the first once-monthly subcutaneous octreotide for acromegaly maintenance treatment. This formulation offers convenient self-administration via a pre-filled autoinjector pen. Clinical trials showed Oczyesa® achieves effective disease control, improves symptoms, and enhances quality of life for acromegaly patients.
